Multiple myeloma: QALY gains from optimal therapy

Drugs and Therapy Perspectives

Volumn 16, Issue 9, 2000, Pages 12-16

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; GROWTH FACTOR; IBANDRONIC ACID; IMMUNOGLOBULIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT INTERFERON; VINCRISTINE;

ANEMIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INFECTION; MULTIPLE MYELOMA; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 0034706802     PISSN: 11720360     EISSN: None     Source Type: Journal    
DOI: 10.2165/00042310-200016090-00004     Document Type: Review

References (18)

1. Therapeutic options in the treatment of multiple myeloma: Pharmacoeconomic and quality-of-life considerations
2. Measurement of health-related quality of life in multiple myeloma
3. Cost-utility analysis of melphalan plus prednisone with or without interferon-α2b in newly diagnosed multiple myeloma
4. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
5. Intensive treatment for multiple myeloma and criteria for complete remission
6. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
7. High-dose therapy in multiple myeloma: An updated analysis of the IFM 90 protocol
8. Intensive therapy in newly diagnosed multiple myeloma patients below 60 years: A prospective, controlled, population based study
9. Health related quality of life of multiple myeloma patients treated with high dose chemotherapy and autologous peripheral blood stem cell transplantation
10. The costs of peripheral blood progenitor cell reinfusion mobilized by granulocyte colony-stimulationg factor following high dose melphalan as compared with conventional therapy in multiple myeloma
11. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma
12. The role of interferon (IFN) as therapy for multiple myeloma: An overview of 24 randomized trials with over 4000 patients
13. Interferon α-2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: A randomized, controlled trial
14. Patient preferences for interferon alfa in multiple myeloma
15. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
16. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
17. Randomised trial of intravenous immunoglobulin as prophylaxis against infections in plateau-phase multiple myeloma